aTyr Pharma, Inc. (ATYR)

Market Cap	93.73M -69.9%
Revenue (ttm)	190,000 -19.1%
Net Income	-75.12M
EPS	-0.84
Shares Out	97.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	932,632
Open	0.9900
Previous Close	0.9900
Day's Range	0.9406 - 1.0100
52-Week Range	0.6400 - 7.2900
Beta	0.58
Analysts	Hold
Price Target	4.20 (+337.59%)
Earnings Date	Mar 17, 2026

About ATYR

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease rela...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: ATYR
• Website: https://atyrpharma.com

Financial Performance

In 2024, aTyr Pharma's revenue was $235,000, a decrease of -33.43% compared to the previous year's $353,000. Losses were -$64.02 million, 27.1% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for ATYR stock is "Hold." The 12-month stock price target is $4.2, which is an increase of 337.59% from the latest price.

Price Target

$4.2

(337.59% upside)

Analyst Consensus: Hold